These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19998528)

  • 1. Octreotide LAR: safety and tolerability issues.
    Bornschein J; Drozdov I; Malfertheiner P
    Expert Opin Drug Saf; 2009 Nov; 8(6):755-68. PubMed ID: 19998528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    Yang LP; Keating GM
    Drugs; 2010 Sep; 70(13):1745-69. PubMed ID: 20731479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide LAR for the treatment of acromegaly.
    Vallette S; Serri O
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):783-93. PubMed ID: 18611118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
    Turner HE; Vadivale A; Keenan J; Wass JA
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):275-80. PubMed ID: 10469005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin agonists for treatment of acromegaly.
    Ben-Shlomo A; Melmed S
    Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
    Pusceddu S; Prinzi N; Raimondi A; Corti F; Buzzoni R; Di Bartolomeo M; Seregni E; Maccauro M; Coppa J; Milione M; Mazzaferro V; de Braud F
    Tumori; 2019 Apr; 105(2):113-120. PubMed ID: 29714658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China].
    Xuan JW; Zhang ZY; Wang YF; Mao ZG; Lu YJ; Wang RZ
    Zhonghua Yi Xue Za Zhi; 2017 Mar; 97(10):765-769. PubMed ID: 28316158
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
    Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
    Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
    Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
    World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey.
    Falconi M; Fazio N; Ferone D; Versari A
    Expert Opin Pharmacother; 2020 Dec; 21(18):2317-2324. PubMed ID: 32990061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues.
    Wahid ST; Marbach P; Stolz B; Miller M; James RA; Ball SG
    Eur J Endocrinol; 2002 Mar; 146(3):295-302. PubMed ID: 11888834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
    Ludlam WH; Anthony L
    Adv Ther; 2011 Oct; 28(10):825-41. PubMed ID: 21964965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Nurses' and Patients' Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR
    Delemer B; Nguyen-Tan-Hon T; Coriat R; Smith D; Schillo F; Raingeard I; Sobhani I; Etienne PL; Decoudier B; Bisot-Locard S; Santos A; Raverot G; Cadiot G
    Adv Ther; 2020 Sep; 37(9):3901-3915. PubMed ID: 32683667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
    Jallad RS; Bronstein MD
    Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.